UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

Zo­genix’s epilep­sy drug Fin­tepla may on­ly have brought in around $100 mil­lion of sales in its first year, but UCB clear­ly be­lieves it can go much, much high­er.

The Bel­gian phar­ma has inked a $1.9 bil­lion deal to buy out Zo­genix, pay­ing $26 per share in cash and of­fer­ing a con­tin­gent val­ue right worth $2 more per share if Fin­tepla lands an ex­tra EU ap­proval by the end of 2023.

But even the up­front marks a 72% pre­mi­um to Cal­i­for­nia-based Zo­genix’s shares, which were trad­ing just north of $15 on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER